127 related articles for article (PubMed ID: 17907963)
1. c-Jun N-terminal kinases as potential therapeutic targets.
Salh B
Expert Opin Ther Targets; 2007 Oct; 11(10):1339-53. PubMed ID: 17907963
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of c-Jun N-terminal kinases: an update.
Koch P; Gehringer M; Laufer SA
J Med Chem; 2015 Jan; 58(1):72-95. PubMed ID: 25415535
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of c-jun-N-terminal kinase (JNK).
LoGrasso P; Kamenecka T
Mini Rev Med Chem; 2008 Jul; 8(8):755-66. PubMed ID: 18673131
[TBL] [Abstract][Full Text] [Related]
4. Small molecule JNK (c-Jun N-terminal kinase) inhibitors.
Siddiqui MA; Reddy PA
J Med Chem; 2010 Apr; 53(8):3005-12. PubMed ID: 20146479
[No Abstract] [Full Text] [Related]
5. Antiepileptic action of c-Jun N-terminal kinase (JNK) inhibition in an animal model of temporal lobe epilepsy.
Tai TY; Warner LN; Jones TD; Jung S; Concepcion FA; Skyrud DW; Fender J; Liu Y; Williams AD; Neumaier JF; D'Ambrosio R; Poolos NP
Neuroscience; 2017 May; 349():35-47. PubMed ID: 28237815
[TBL] [Abstract][Full Text] [Related]
6. p38 pathway kinases as anti-inflammatory drug targets.
Schindler JF; Monahan JB; Smith WG
J Dent Res; 2007 Sep; 86(9):800-11. PubMed ID: 17720847
[TBL] [Abstract][Full Text] [Related]
7. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
8. A c-Jun NH2-terminal kinase inhibitor SP600125 (anthra[1,9-cd]pyrazole-6 (2H)-one) blocks activation of pancreatic stellate cells.
Masamune A; Kikuta K; Suzuki N; Satoh M; Satoh K; Shimosegawa T
J Pharmacol Exp Ther; 2004 Aug; 310(2):520-7. PubMed ID: 15056726
[TBL] [Abstract][Full Text] [Related]
9. c-Jun N-terminal kinase binding domain-dependent phosphorylation of mitogen-activated protein kinase kinase 4 and mitogen-activated protein kinase kinase 7 and balancing cross-talk between c-Jun N-terminal kinase and extracellular signal-regulated kinase pathways in cortical neurons.
Repici M; Mare L; Colombo A; Ploia C; Sclip A; Bonny C; Nicod P; Salmona M; Borsello T
Neuroscience; 2009 Mar; 159(1):94-103. PubMed ID: 19135136
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.
Messoussi A; Feneyrolles C; Bros A; Deroide A; Daydé-Cazals B; Chevé G; Van Hijfte N; Fauvel B; Bougrin K; Yasri A
Chem Biol; 2014 Nov; 21(11):1433-43. PubMed ID: 25442375
[TBL] [Abstract][Full Text] [Related]
11. Identification of c-Jun N-terminal kinase as a therapeutic target for abdominal aortic aneurysm.
Yoshimura K; Aoki H; Ikeda Y; Furutani A; Hamano K; Matsuzaki M
Ann N Y Acad Sci; 2006 Nov; 1085():403-6. PubMed ID: 17182964
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic promise of JNK ATP-noncompetitive inhibitors.
Bogoyevitch MA
Trends Mol Med; 2005 May; 11(5):232-9. PubMed ID: 15882611
[TBL] [Abstract][Full Text] [Related]
13. Galloyl benzamide-based compounds modulating tumour necrosis factor α-stimulated c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signalling pathways.
Leo V; Stefanachi A; Nacci C; Leonetti F; de Candia M; Carotti A; Altomare CD; Montagnani M; Cellamare S
J Pharm Pharmacol; 2015 Oct; 67(10):1380-92. PubMed ID: 26078032
[TBL] [Abstract][Full Text] [Related]
14. JNK: bridging the insulin signaling and inflammatory pathway.
Liu G; Rondinone CM
Curr Opin Investig Drugs; 2005 Oct; 6(10):979-87. PubMed ID: 16259218
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors.
Humphries PS; Lafontaine JA; Agree CS; Alexander D; Chen P; Do QQ; Li LY; Lunney EA; Rajapakse RJ; Siegel K; Timofeevski SL; Wang T; Wilhite DM
Bioorg Med Chem Lett; 2009 Apr; 19(8):2099-102. PubMed ID: 19327989
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor-mediated regulation of the anti-atherogenic enzyme CYP27A1 involves the JNK/c-jun pathway.
Norlin M; Pettersson H; Tang W; Wikvall K
Arch Biochem Biophys; 2011 Feb; 506(2):236-41. PubMed ID: 21134350
[TBL] [Abstract][Full Text] [Related]
17. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of targeting mixed lineage kinases in cancer and inflammation.
Gallo KA; Ellsworth E; Stoub H; Conrad SE
Pharmacol Ther; 2020 Mar; 207():107457. PubMed ID: 31863814
[TBL] [Abstract][Full Text] [Related]
19. c-Jun N-terminal kinase-dependent mechanisms in respiratory disease.
Bennett BL
Eur Respir J; 2006 Sep; 28(3):651-61. PubMed ID: 16946096
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive drug azathioprine reduces aneurysm progression through inhibition of Rac1 and c-Jun-terminal-N-kinase in endothelial cells.
Marinkovic G; Hibender S; Hoogenboezem M; van Broekhoven A; Girigorie AF; Bleeker N; Hamers AA; Stap J; van Buul JD; de Vries CJ; de Waard V
Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2380-8. PubMed ID: 23950142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
